WO2012004276A3 - Marqueurs biologiques multiprotéines de la sclérose latérale amyotrophique dans les cellules mononucléaires du sang périphérique, procédés et kits de diagnostic - Google Patents

Marqueurs biologiques multiprotéines de la sclérose latérale amyotrophique dans les cellules mononucléaires du sang périphérique, procédés et kits de diagnostic Download PDF

Info

Publication number
WO2012004276A3
WO2012004276A3 PCT/EP2011/061344 EP2011061344W WO2012004276A3 WO 2012004276 A3 WO2012004276 A3 WO 2012004276A3 EP 2011061344 W EP2011061344 W EP 2011061344W WO 2012004276 A3 WO2012004276 A3 WO 2012004276A3
Authority
WO
WIPO (PCT)
Prior art keywords
lateral sclerosis
amyotrophic lateral
multiprotein
biomarkers
kits
Prior art date
Application number
PCT/EP2011/061344
Other languages
English (en)
Other versions
WO2012004276A2 (fr
Inventor
Valentina Bonetto
Caterina Bendotti
Gabriele Mora
Massimo Corbo
Original Assignee
Fondazione Telethon
Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondazione Telethon, Fondazione Salvatore Maugeri Clinica Del Lavoro E Della Riabilitazione filed Critical Fondazione Telethon
Publication of WO2012004276A2 publication Critical patent/WO2012004276A2/fr
Publication of WO2012004276A3 publication Critical patent/WO2012004276A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un procédé et un kit de diagnostic pour diagnostiquer et/ou pour effectuer des prévisions pronostiques et/ou pour suivre l'efficacité d'une thérapie de la sclérose latérale amyotrophique (SLA) chez un sujet.
PCT/EP2011/061344 2010-07-06 2011-07-05 Marqueurs biologiques multiprotéines de la sclérose latérale amyotrophique dans les cellules mononucléaires du sang périphérique, procédés et kits de diagnostic WO2012004276A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36173010P 2010-07-06 2010-07-06
US61/361,730 2010-07-06

Publications (2)

Publication Number Publication Date
WO2012004276A2 WO2012004276A2 (fr) 2012-01-12
WO2012004276A3 true WO2012004276A3 (fr) 2012-03-08

Family

ID=44453810

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/061344 WO2012004276A2 (fr) 2010-07-06 2011-07-05 Marqueurs biologiques multiprotéines de la sclérose latérale amyotrophique dans les cellules mononucléaires du sang périphérique, procédés et kits de diagnostic

Country Status (1)

Country Link
WO (1) WO2012004276A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243946A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of membrane proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2019036577A1 (fr) * 2017-08-18 2019-02-21 University Of South Carolina Détection d'une modification dérivée d'ester de fumarate dans un échantillon d'essai
WO2019217916A1 (fr) * 2018-05-10 2019-11-14 The Methodist Hospital Procédés de pronostic et de gestion de maladie
AU2022233849A1 (en) * 2021-03-08 2023-10-12 Akershus Universitetssykehus Hf Clearance assay

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080289964A1 (en) * 2005-08-24 2008-11-27 Ira Leonard Goldknopf Assays for diagnosis and therapeutics employing similarities and differences in blood serum concentrations of 3 forms of complement C3c and related protein biomarkers between amyotrophic lateral sclerosis and Parkinson's disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1991869A2 (fr) 2006-02-17 2008-11-19 Paolo La Colla Procédés de diagnostic de maladies prolifératives et/ou conformationnelles
US8354236B2 (en) 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
WO2010148323A2 (fr) 2009-06-18 2010-12-23 Whittemore Peterson Institute For Neuro-Immune Disease Diagnostic et traitement de maladies ou troubles associés au virus de la leucémie murine xénotrope

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080289964A1 (en) * 2005-08-24 2008-11-27 Ira Leonard Goldknopf Assays for diagnosis and therapeutics employing similarities and differences in blood serum concentrations of 3 forms of complement C3c and related protein biomarkers between amyotrophic lateral sclerosis and Parkinson's disease

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GIOVANNI NARDO ET AL: "Nitroproteomics of Peripheral Blood Mononuclear Cells from Patients and a Rat Model of ALS", ANTIOXIDANTS & REDOX SIGNALING, 1 July 2009 (2009-07-01), pages 1559 - 1567, XP055005303, Retrieved from the Internet <URL:http://www.liebertonline.com/doi/pdf/10.1089/ars.2009.2548> [retrieved on 20110822] *
INVITROGEN: "ATP synthase subunit beta monoclonal antibody", 1 July 2010 (2010-07-01), XP055005400, Retrieved from the Internet <URL:http://probes.invitrogen.com/media/pis/mp21351.pdf> [retrieved on 20110823] *
TURNER MARTIN R ET AL: "Biomarkers in amyotrophic lateral sclerosis", LANCET NEUROLOGY JAN 2009 LNKD- PUBMED:19081518,, vol. 8, no. 1, 1 January 2009 (2009-01-01), pages 94 - 109, XP002654835 *

Also Published As

Publication number Publication date
WO2012004276A2 (fr) 2012-01-12

Similar Documents

Publication Publication Date Title
WO2012004276A3 (fr) Marqueurs biologiques multiprotéines de la sclérose latérale amyotrophique dans les cellules mononucléaires du sang périphérique, procédés et kits de diagnostic
WO2014028884A3 (fr) Diagnostic du cancer au moyen de biomarqueurs
WO2011092285A3 (fr) Moyens et méthodes de diagnostic d&#39;une insuffisance cardiaque chez un sujet
WO2011054893A3 (fr) Marqueurs biologiques prédictifs de l&#39;évolution d&#39;une fibrose
WO2011151252A3 (fr) Moyens et méthodes de diagnostic du cancer du pancréas chez un sujet
EP4303584A3 (fr) Procédés de détection de signatures de maladies ou pathologies dans des liquides biologiques
WO2012076553A3 (fr) Biomarqueurs et paramètres des troubles d&#39;hypertension de la grossesse
WO2013063155A3 (fr) Diagnostic compagnon pour le traitement avec un agent anti-hyaluronane et procédés d&#39;utilisation dudit diagnostic
WO2012110878A3 (fr) Méthode de diagnostic du cancer et trousse de diagnostic à l&#39;aide de la mesure de l&#39;activité des cellules nk
IN2014CN04326A (fr)
WO2011015944A3 (fr) Utilisation d&#39;adn libre en tant que prédicteur précoce de la gravité d&#39;une pancréatite aiguë
WO2013066369A3 (fr) Procédés de détection de maladie du greffon contre l&#39;hôte
WO2014078468A3 (fr) Biomarqueurs destinés à prédire une réponse clinique de patients cancéreux suite à un traitement avec un agent immunothérapeutique
WO2012012704A3 (fr) Procédés de détection de maladies ou d&#39;états associés au rein
WO2017027391A3 (fr) Anomalies génétiques dans des dyscrasies de cellules du plasma
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
WO2011163214A3 (fr) Profils de micro-arn pour une évaluation de la sclérose en plaques
MX2016008045A (es) Biomarcadores de lipogenesis de novo y metodos de uso de los mismos.
WO2014053996A3 (fr) Anticorps dirigés contre le microbiome, facteurs de stress et marqueurs de mastocytes servant de marqueurs de diagnostic du sci
WO2013066879A3 (fr) Récepteur soluble de l&#39;urokinase (supar) dans la néphropathie diabétique
WO2013079981A3 (fr) Procédés basés sur des marqueurs biologiques et biopuces pour aider au diagnostic d&#39;un accident vasculaire cérébral
WO2007094027A8 (fr) Procédés de diagnostic de maladies prolifératives et/ou conformationnelles
WO2015069883A8 (fr) Fraction oxydée de l&#39;adn extracellulaire utilisable en tant que biomarqueur du stress et ses procédés d&#39;utilisation
WO2011084548A3 (fr) Méthodes et compositions permettant de dépister la forme familiale récessive de la fsgs et leurs utilisations
IN2015MN00140A (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11733625

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11733625

Country of ref document: EP

Kind code of ref document: A2